AstraZeneca highlights continued progress of oncology pipeline at ASCO 2016
73 abstracts presented at ASCO with 19 related to Lynparza and new potential medicines targeting...
AbbVies Inc Leadership in Gastroenterology Showcased at Digestive Disease Week with New HUMIRA Long-Term,...
Data presentations further evaluate HUMIRA® (adalimumab) for the treatment of inflammatory bowel diseases including moderate...
Spark Therapeutics, Pfizer Inc announce data from initial subjects in hemophilia B trial
Subjects received one-time administration of a highly optimized gene therapy at initial low dose...
Merck & Co Inc Final overall survival data from KEYNOTE-006 and KEYNOTE-001 in Advanced...
Final Overall Survival Data from KEYNOTE-006 To Be Presented at ASCO; KEYTRUDA, the First Anti-PD-1...
GlaxoSmithKline presents new data from Breo Ellipta SUMMIT study in patients with COPD at...
GlaxoSmithKline and Innoviva, Inc announced that GlaxoSmithKline plc (GSK) presented new data at the American...
GlaxoSmithKline presents positive data for Anoro Ellipta in COPD patients who remained symptomatic on...
GlaxoSmithKline and Innoviva Inc announced results from data presented at the American Thoracic Society (ATS)...
Merck and Pfizer to Present Avelumab Data in Seven Different Cancers at ASCO Annual...
14 avelumab abstracts at ASCO 2016 highlight significant progress being made by the collaboration...
Amgen Inc Data To Be Presented At ASCO 2016 Demonstrates More Insights Into Treatment...
New Analysis From Phase 3 Trial of Kyprolis® (Carfilzomib) Combination Treatment in Relapsed Multiple Myeloma...
AstraZeneca reports the positive Top-Line Results from the Benralizumab Phase III Programme in Severe...
Kyowa Hakko Kirin Co Ltd announced that AstraZeneca obtained the positive top-line results that benralizumab,...
FDA approves For Eisais Anticancer Agent Lenvima In Combination With Everolimus as Treatment For...
Eisai Co Ltd announced that its U.S. subsidiary Eisai Inc. has received approval from the...
